NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET

Company Participants

Matthew Duffy - Chief Business Officer
Dr. Jonathan Javitt - Founder, Chairman and Chief Scientist
Stephen Willard - Chief Executive Officer
Richard Narido - Chief Financial Officer and Treasurer

Conference Call Participants

Ed Woo - Ascendiant

Operator

Good afternoon, everyone. And welcome to the NRx Pharmaceuticals Incorporated Second Quarter of 2024 Results Conference Call. Currently, all participants are in a listen-only mode. As a reminder, this conference call is being recorded.

I will now turn the call over to Matthew Duffy, the company’s Chief Business Officer. Please go ahead.

Matthew Duffy

Thank you, Franzi, and welcome, everyone. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under the U.S. Federal Security Act.

These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC.

The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise forward-looking statements. Information presented on this call is contained in the press release issued today and in the company’s Form 10-Q, which may be accessed from the Investors page of the NRx Pharmaceuticals website.

Joining me today are Dr. Jonathan Javitt, our Founder and Chairman and Chief Scientist; Stephen Willard, our Chief Executive Officer; and Richard Narido, Chief Financial Officer and Treasurer.

Stephen and Jonathan will provide a summary of our company’s progress. Rich will review the company’s financial results and then Jonathan will review upcoming milestones before making closing comments. Following the prepared remarks, we will address investor questions.

I’ll now turn you over -- the call over to Jonathan.

Dr. Jonathan Javitt

Thank you, Matt. Good afternoon, everybody. Thank you for joining us. Steve, Matt, Rich, the rest of the team have now reached a point where years of hard work are beginning to bear visible fruit. We’ve reached three key inflection points on scientific, business and financing fronts in advancing our business.

First, on the scientific front, we’re poised to file two NDAs for our product candidates in the coming months. NRX-100 for clinic-based treatment of suicidal depression, that is intravenous ketamine and NRX-101 for home-based treatment of bipolar depression in patients with suicidality or akathisia. That’s an oral combination of D-cycloserine and lurasidone.